Search Press releases Keywords From To 10 Nov 2023 UCB receives CHMP positive opinion for rozanolixizumab for treatment of adults with generalized myasthenia gravis in Europe Read More 10 Nov 2023 UCB Presents New Five-Year Data on BIMZELX[®]▼(bimekizumab) in Ankylosing Spondylitis at ACR Convergence 2023 Read More 9 Nov 2023 UCB successfully completes its offer to the public of fixed rate notes and decides to early terminate the subscription period Read More 7 Nov 2023 UCB launches an offer to the public of 6-year 5.20% fixed rate notes in Belgium and in Luxembourg Read More 1 Nov 2023 UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session Read More 18 Oct 2023 BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis Read More Pagination First page Previous page Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
